63,630 Shares in Becton, Dickinson and Company $BDX Purchased by Andra AP fonden

Key Points

• Andra AP fonden purchased 63,630 Becton, Dickinson and Company shares during the second quarter, valued at approximately $9.6 million. Institutional investors collectively own 86.97% of BDX.
• Analyst sentiment is mixed, with eight Buy, eight Hold and one Sell rating; the stock has an average rating of “Hold” and a consensus price target of $187.67.
• BDX shares opened at $183.30, near their 52-week high, after the company reported quarterly revenue of $4.98 billion and EPS of $3.23, both above expectations. The company also declared a quarterly dividend of $1.05 per share, representing a 2.3% yield.

Andra AP fonden purchased a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 63,630 shares of the medical instruments supplier's stock, valued at approximately $9,629,000.

Several other large investors have also bought and sold shares of BDX. Brown Lisle Cummings Inc. raised its holdings in Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier's stock worth $97,000 after acquiring an additional 54 shares during the last quarter. Elevation Point Wealth Partners LLC grew its holdings in Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier's stock valued at $256,000 after purchasing an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC lifted its holdings in Becton, Dickinson and Company by 1.1% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier's stock valued at $834,000 after purchasing an additional 62 shares in the last quarter. NorthRock Partners LLC boosted its holdings in Becton, Dickinson and Company by 2.0% in the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier's stock worth $499,000 after buying an additional 65 shares during the period. Finally, BOK Financial Private Wealth Inc. grew its position in shares of Becton, Dickinson and Company by 7.3% during the second quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier's stock worth $162,000 after purchasing an additional 73 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BDX has been the topic of a number of research reports. The Goldman Sachs Group reduced their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a report on Wednesday, May 27th. TD Cowen increased their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Finally, Bank of America increased their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Monday, August 31st. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $187.67.

Becton, Dickinson and Company Trading Up 1.4%

Shares of BDX stock opened at $183.30 on Wednesday. The stock has a 50 day simple moving average of $176.65 and a 200-day simple moving average of $160.75. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The company has a market cap of $50.51 billion, a price-to-earnings ratio of 55.21, a PEG ratio of 12.74 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's payout ratio is presently 126.51%.

Insider Buying and Selling

In other news, EVP Michael Feld sold 165 shares of the company's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,905 shares of company stock valued at $1,263,354 in the last ninety days. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.